Skip to main content

NYSE:ABC - AmerisourceBergen Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $123.78
  • Forecasted Upside: 2.41 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$120.86
▲ +3.23 (2.75%)
1 month | 3 months | 12 months
Get New AmerisourceBergen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$123.78
▲ +2.41% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for AmerisourceBergen in the last 3 months. The average price target is $123.78, with a high forecast of $150.00 and a low forecast of $88.00. The average price target represents a 2.41% upside from the last price of $120.86.

Buy

The current consensus among 10 contributing investment analysts is to buy stock in AmerisourceBergen. This rating has held steady since November 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
11/16/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
2/14/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/14/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/12/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/10/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/8/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/9/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/6/2021BarclaysBoost Price TargetEqual Weight$122.00 ➝ $130.00Low
i
2/9/2021MizuhoBoost Price TargetNeutral$104.00 ➝ $114.00Low
i
2/8/2021Morgan StanleyBoost Price TargetOverweight$130.00 ➝ $138.00Medium
i
2/8/2021CowenBoost Price TargetOutperform$145.00 ➝ $150.00Low
i
2/5/2021Credit Suisse GroupBoost Price TargetOutperform$123.00 ➝ $127.00Low
i
2/4/2021Evercore ISIUpgradeIn-Line ➝ OutperformLow
i
2/1/2021CowenBoost Price TargetOutperform$129.00 ➝ $145.00Low
i
1/21/2021ArgusBoost Price TargetBuy$120.00 ➝ $140.00Medium
i
1/7/2021Deutsche Bank AktiengesellschaftBoost Price TargetHold$111.00 ➝ $115.00N/A
i
1/6/2021Bank of AmericaUpgradeUnderperform ➝ NeutralN/A
i
11/13/2020MizuhoBoost Price TargetNeutral$100.00 ➝ $104.00Medium
i
11/9/2020Credit Suisse GroupBoost Price TargetOutperform$118.00 ➝ $123.00Low
i
11/9/2020Morgan StanleyBoost Price TargetOverweight$121.00 ➝ $130.00Low
i
11/6/2020Deutsche Bank AktiengesellschaftBoost Price TargetHold$104.00 ➝ $111.00Low
i
8/10/2020UBS GroupBoost Price TargetBuy$99.00 ➝ $112.00Low
i
8/10/2020Credit Suisse GroupBoost Price TargetOutperform$111.00 ➝ $118.00Low
i
Rating by Jailendra Singh at Credit Suisse Group AG
8/6/2020Morgan StanleyBoost Price TargetOverweight$112.00 ➝ $121.00High
i
7/21/2020Bank of AmericaBoost Price TargetUnderperform$85.00 ➝ $88.00Medium
i
6/15/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$94.00 ➝ $112.00Medium
i
5/15/2020UBS GroupLower Price TargetBuy$108.00 ➝ $99.00High
i
5/11/2020Deutsche Bank AktiengesellschaftBoost Price TargetHold$93.00 ➝ $98.00Medium
i
5/8/2020Morgan StanleyBoost Price TargetEqual Weight$84.00 ➝ $94.00High
i
4/22/2020Credit Suisse GroupInitiated CoverageBuy$105.00Low
i
Rating by Jailendra Singh at Credit Suisse Group AG
4/1/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$93.00 ➝ $106.00Medium
i
3/27/2020Morgan StanleyLower Price TargetEqual Weight$98.00 ➝ $84.00Medium
i
2/7/2020Robert W. BairdUpgradeNeutral ➝ Outperform$112.00Medium
i
2/2/2020Credit Suisse GroupReiterated RatingBuy$98.00Low
i
1/31/2020Robert W. BairdBoost Price TargetNeutral$93.00 ➝ $94.00High
i
1/31/2020Deutsche Bank AktiengesellschaftBoost Price TargetHold$79.00 ➝ $93.00High
i
1/19/2020BarclaysReiterated RatingHold$100.00Low
i
11/18/2019ArgusReiterated RatingBuy$110.00Low
i
9/12/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold$91.00High
i
9/6/2019Morgan StanleyLower Price TargetEqual Weight$91.00 ➝ $83.00N/A
i
6/3/2019ArgusLower Price TargetBuy$115.00 ➝ $100.00Medium
i
4/11/2019GuggenheimInitiated CoverageBuyLow
i
4/10/2019Bank of AmericaDowngradeBuy ➝ Underperform$95.00 ➝ $76.00High
i
4/2/2019Wolfe ResearchInitiated CoverageMarket PerformHigh
i
1/17/2019UBS GroupInitiated CoverageBuy ➝ Buy$89.00Medium
i
1/6/2019BarclaysReiterated RatingHold$84.00Low
i
12/3/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$88.00 ➝ $91.00Low
i
Rating by Ricky Goldwasser at Morgan Stanley
11/30/2018Royal Bank of CanadaLower Price TargetSector Perform ➝ Hold$90.00 ➝ $87.00Low
i
Rating by George Hill at Royal Bank of Canada
11/7/2018Royal Bank of CanadaSet Price TargetHold$90.00Low
i
Rating by George Hill at Royal Bank of Canada
9/19/2018MizuhoReiterated RatingNeutralMedium
i
Rating by A. Hynes at Mizuho
8/12/2018MizuhoReiterated RatingHold$90.00Low
i
8/3/2018Robert W. BairdReiterated RatingHold$89.00Medium
i
7/20/2018Robert W. BairdDowngradeOutperform ➝ NeutralLow
i
7/20/2018Robert W. BairdReiterated RatingOutperform ➝ Neutral$94.00Low
i
7/3/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$97.00 ➝ $88.00Low
i
4/2/2018Royal Bank of CanadaSet Price TargetHold$101.00Medium
i
Rating by George Hill at Royal Bank of Canada
3/27/2018BarclaysLower Price TargetEqual Weight ➝ Equal Weight$104.00 ➝ $95.00Low
i
3/8/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$104.00Low
i
3/5/2018ArgusBoost Price TargetBuy$93.96 ➝ $115.00Low
i
2/27/2018CowenReiterated RatingBuy$108.00Low
i
Rating by Charles Rhyee at Cowen Inc
2/27/2018Bank of AmericaInitiated CoverageBuy ➝ Buy$111.00High
i
2/8/2018Needham & Company LLCLower Price TargetBuy ➝ Buy$117.00 ➝ $113.00Medium
i
Rating by Kevin Caliendo at Needham & Company LLC
2/7/2018Jefferies Financial GroupSet Price TargetHold$95.00Medium
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
2/7/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$105.00 ➝ $112.00Medium
i
2/7/2018Royal Bank of CanadaReiterated RatingHold$102.00Medium
i
1/24/2018MizuhoSet Price TargetHold$100.00Low
i
Rating by Ann Hynes at Mizuho
1/23/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$88.00 ➝ $108.00Low
i
Rating by Kevin Caliendo at Needham & Company LLC
1/4/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$105.00Medium
i
1/2/2018SVB LeerinkSet Price TargetBuy$90.00 ➝ $105.00Low
i
Rating by David Larsen at SVB Leerink LLC
12/15/2017The Goldman Sachs GroupUpgradeNeutral ➝ BuyHigh
i
12/12/2017CowenSet Price TargetBuy$107.00Low
i
Rating by Charles Rhyee at Cowen Inc
12/4/2017Deutsche Bank AktiengesellschaftInitiated CoverageBuy$97.00High
i
12/1/2017Robert W. BairdSet Price TargetBuy$99.00High
i
Rating by Eric Coldwell at Robert W. Baird
11/22/2017Needham & Company LLCBoost Price TargetBuy$86.00 ➝ $88.00N/A
i
Rating by Kevin Caliendo at Needham & Company LLC
11/6/2017Robert W. BairdReiterated RatingBuy$96.00N/A
i
11/6/2017Needham & Company LLCLower Price TargetBuy$93.00 ➝ $86.00N/A
i
Rating by Kevin Caliendo at Needham & Company LLC
10/29/2017Jefferies Financial GroupSet Price TargetHold$85.00N/A
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
10/24/2017MizuhoSet Price TargetHold$92.00N/A
i
10/24/2017Needham & Company LLCSet Price TargetBuy$93.00N/A
i
Rating by Kevin Caliendo at Needham & Company LLC
10/10/2017CowenUpgradeMarket Perform ➝ OutperformN/A
i
10/5/2017Robert W. BairdUpgradeNeutral ➝ Outperform$89.00 ➝ $96.00N/A
i
9/19/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$87.00Medium
i
9/14/2017Morgan StanleyDowngradeOverweight ➝ Equal WeightHigh
i
9/10/2017Needham & Company LLCReiterated RatingBuy$91.00Medium
i
8/29/2017Jefferies Financial GroupSet Price TargetHold$95.00Low
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
8/7/2017SVB LeerinkSet Price TargetOutperform ➝ Buy$100.00 ➝ $90.00Low
i
Rating by David Larsen at SVB Leerink LLC
8/4/2017UBS GroupLower Price TargetNeutral ➝ Neutral$94.00 ➝ $87.00Low
i
7/13/2017Credit Suisse GroupReiterated RatingOutperform ➝ Buy$95.00Low
i
6/30/2017Bank of AmericaDowngradeBuy ➝ Neutral$95.76 ➝ $94.00Medium
i
6/21/2017Jefferies Financial GroupReiterated RatingHold$95.00Low
i
5/30/2017MizuhoBoost Price TargetNeutral ➝ Neutral$83.00 ➝ $93.00Low
i
5/17/2017Jefferies Financial GroupInitiated CoverageHold ➝ Hold$95.00High
i
4/4/2017Needham & Company LLCInitiated CoverageBuy ➝ Buy$99.00Low
i
2/5/2017Credit Suisse GroupReiterated RatingBuyN/A
i
1/31/2017Morgan StanleyUpgradeEqual Weight ➝ OverweightN/A
i
1/17/2017SVB LeerinkUpgradeMarket Perform ➝ Outperform$95.00N/A
i
Rating by D. Larsen at SVB Leerink LLC
1/12/2017Bank of AmericaUpgradeNeutral ➝ Buy$94.00N/A
i
1/3/2017MizuhoDowngradeBuy ➝ Neutral$83.00N/A
i
11/10/2016Morgan StanleyUpgradeEqual Weight ➝ Overweight$84.00 ➝ $86.00N/A
i
11/9/2016MizuhoUpgradeNeutral ➝ Buy$83.00N/A
i
11/4/2016SVB LeerinkDowngradeOutperform ➝ Market Perform$75.00N/A
i
Rating by D. Larsen at SVB Leerink LLC
10/10/2016Cleveland ResearchDowngradeBuy ➝ NeutralN/A
i
10/7/2016SVB LeerinkReiterated RatingBuy$100.00N/A
i
10/5/2016UBS GroupInitiated CoverageNeutralN/A
i
10/4/2016Avondale PartnersUpgradeMarket Perform ➝ OutperformN/A
i
Rating by G. Bolan at Avondale Partners
9/12/2016Morgan StanleyReiterated RatingHold$89.00N/A
i
8/26/2016Credit Suisse GroupReiterated RatingBuy$98.00N/A
i
Rating by Edward Kelly at Credit Suisse Group AG
8/26/2016SVB LeerinkBoost Price TargetOutperform$100.00N/A
i
8/11/2016MizuhoBoost Price TargetNeutral$80.00 ➝ $90.00N/A
i
8/3/2016SVB LeerinkReiterated RatingBuyN/A
i
8/3/2016Deutsche Bank AktiengesellschaftBoost Price TargetHold$83.00 ➝ $96.00N/A
i
Rating by George Hill at Deutsche Bank Aktiengesellschaft
8/3/2016CitigroupBoost Price TargetBuy$100.00 ➝ $105.00N/A
i
8/3/2016BarclaysBoost Price TargetEqual Weight$83.00 ➝ $89.00N/A
i
Rating by Eric Percher at Barclays PLC
8/3/2016(FBRC)Boost Price TargetMkt Perform$84.00 ➝ $90.00N/A
i
8/2/2016Evercore ISIReiterated RatingHold$93.50N/A
i
6/7/2016Bank of AmericaReiterated RatingNeutralN/A
i
6/4/2016ArgusReiterated RatingBuyN/A
i
Rating by David Toung at Argus
6/1/2016Raymond JamesDowngradeOutperform ➝ Market PerformN/A
i
(Data available from 5/9/2016 forward)
AmerisourceBergen logo
AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; offers specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets, as well as provides demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was founded in 1985 and is headquartered in Chesterbrook, Pennsylvania.
Read More

Today's Range

Now: $120.86
$117.26
$121.37

50 Day Range

MA: $118.54
$113.77
$125.85

52 Week Range

Now: $120.86
$81.51
$125.86

Volume

1,257,060 shs

Average Volume

1,161,061 shs

Market Capitalization

$24.74 billion

P/E Ratio

N/A

Dividend Yield

1.50%

Beta

0.57

Frequently Asked Questions

What sell-side analysts currently cover shares of AmerisourceBergen?

The following equities research analysts have issued reports on AmerisourceBergen in the last year: Argus, Bank of America Co., Barclays PLC, Cowen Inc, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Evercore ISI, Mizuho, Morgan Stanley, TheStreet, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for ABC.

What is the current price target for AmerisourceBergen?

9 Wall Street analysts have set twelve-month price targets for AmerisourceBergen in the last year. Their average twelve-month price target is $123.78, suggesting a possible upside of 2.4%. Cowen Inc has the highest price target set, predicting ABC will reach $150.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $88.00 for AmerisourceBergen in the next year.
View the latest price targets for ABC.

What is the current consensus analyst rating for AmerisourceBergen?

AmerisourceBergen currently has 4 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ABC will outperform the market and that investors should add to their positions of AmerisourceBergen.
View the latest ratings for ABC.

What other companies compete with AmerisourceBergen?

Other companies that are similar to AmerisourceBergen include McKesson, Cardinal Health, Henry Schein, Patterson Companies and Owens & Minor.

How do I contact AmerisourceBergen's investor relations team?

AmerisourceBergen's physical mailing address is 1300 MORRIS DRIVE, CHESTERBROOK PA, 19087. The company's listed phone number is 610-727-7000 and its investor relations email address is [email protected] The official website for AmerisourceBergen is www.amerisourcebergen.com.